At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ODD ODDITY Tech Ltd.
Post-Mkt 07-24 17:04:22 EDT
15.34
-0.19
-1.22%
盘后15.34
+0.000.00%
16:10 EDT
High16.09Low15.14Vol502.77K
Open15.54D1 Closing15.53Amplitude6.12%
Mkt Cap707.55MTradable Cap439.18MTotal Shares46.12M
T/O7.76MT/O Rate1.76%Tradable Shares28.63M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

ODDITY to Announce Second Quarter 2026 Financial Results on September 9, 2026
GlobeNewswire  ·  07-23 04:05
ODDITY to Announce Second Quarter 2026 Financial Results on September 9, 2026
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
GlobeNewswire  ·  07-21
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Oddity Tech CFO Lindsay Drucker Mann Disposes of USD 1.65 Million in Common Shares
Reuters  ·  07-01
Oddity Tech CFO Lindsay Drucker Mann Disposes of USD 1.65 Million in Common Shares
Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
GlobeNewswire  ·  06-30
Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
GlobeNewswire  ·  06-22
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
GlobeNewswire  ·  06-22
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
Oddity Tech board expands share buyback distribution up to $200 million under Israeli Companies Law
Reuters  ·  06-17
Oddity Tech board expands share buyback distribution up to $200 million under Israeli Companies Law
ODDITY Tech Sets July 29, 2026 AGM to Vote on Board, Auditor and Governance Matters
TIPRANKS  ·  06-17
ODDITY Tech Sets July 29, 2026 AGM to Vote on Board, Auditor and Governance Matters
Oddity Tech announces annual shareholder meeting
Reuters  ·  06-17
Oddity Tech announces annual shareholder meeting
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
GlobeNewswire  ·  06-15
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
Oddity Tech Unit to Repurchase $50 Million of Exchangeable Senior Notes
MT Newswires Live  ·  06-12
Oddity Tech Unit to Repurchase $50 Million of Exchangeable Senior Notes
ODDITY Tech to Repurchase $50 Million of Exchangeable Notes at Discount
TIPRANKS  ·  06-12
ODDITY Tech to Repurchase $50 Million of Exchangeable Notes at Discount
Oddity Tech: Unit Entered Into Separate, Privately Negotiated Repurchase Deals
THOMSON REUTERS  ·  06-12
Oddity Tech: Unit Entered Into Separate, Privately Negotiated Repurchase Deals
Oddity Tech: Deals With Holders of $50 Mln in Aggregate Principal Amount of 0% Exchangeable Senior Notes Due 2030 of Oddity Finance
THOMSON REUTERS  ·  06-12
Oddity Tech: Deals With Holders of $50 Mln in Aggregate Principal Amount of 0% Exchangeable Senior Notes Due 2030 of Oddity Finance
Oddity Tech Ltd: Repurchases Expected to Close on June 17, 2026 for Purchase Price of $35 Mln- SEC Filing
THOMSON REUTERS  ·  06-12
Oddity Tech Ltd: Repurchases Expected to Close on June 17, 2026 for Purchase Price of $35 Mln- SEC Filing
Oddity Tech unit repurchases $50 million of 0% exchangeable senior notes due 2030 for $35 million
Reuters  ·  06-12
Oddity Tech unit repurchases $50 million of 0% exchangeable senior notes due 2030 for $35 million
GSK announces momelotinib granted ODD from U.S. FDA, EMA
TIPRANKS  ·  06-12
GSK announces momelotinib granted ODD from U.S. FDA, EMA
Analysts Have Conflicting Sentiments on These Technology Companies: Megaport (OtherMGPPF), ODDITY Tech Ltd. Class A (ODD) and Netskope, Inc. (NTSK)
TIPRANKS  ·  06-06
Analysts Have Conflicting Sentiments on These Technology Companies: Megaport (OtherMGPPF), ODDITY Tech Ltd. Class A (ODD) and Netskope, Inc. (NTSK)
Wall Street Analysts Are Neutral on Top Technology Picks
TIPRANKS  ·  06-04
Wall Street Analysts Are Neutral on Top Technology Picks
Oddity price target lowered to $15 from $23 at Evercore ISI
TIPRANKS  ·  06-04
Oddity price target lowered to $15 from $23 at Evercore ISI

Introduction

Company Name.
ODDITY Tech Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Oddity Tech Ltd. operates as a consumer tech company that builds and scales digital-first brands to disrupt beauty and wellness industries. The company serves consumers worldwide through its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. It owns IL MAKIAGE and SpoiledChild brands. The company was incorporated in 2013 and is headquartered in Tel Aviv, Israel with additional office in New York, New York.
Issue price:
--